{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:15:29Z","timestamp":1777364129200,"version":"3.51.4"},"reference-count":5,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cerebrovasc Dis"],"published-print":{"date-parts":[[2009]]},"abstract":"<i>Background:<\/i> Around 15% of patients die or become dependent after cerebral vein and dural sinus thrombosis (CVT). <i>Method:<\/i> We used the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) sample (624 patients, with a median follow-up time of 478 days) to develop a Cox proportional hazards regression model to predict outcome, dichotomised by a modified Rankin Scale score >2. From the model hazard ratios, a risk score was derived and a cut-off point selected. The model and the score were tested in 2 validation samples: (1) the prospective Cerebral Venous Thrombosis Portuguese Collaborative Study Group (VENOPORT) sample with 91 patients; (2) a sample of 169 consecutive CVT patients admitted to 5 ISCVT centres after the end of the ISCVT recruitment period. Sensitivity, specificity, c statistics and overall efficiency to predict outcome at 6 months were calculated. <i>Results:<\/i> The model (hazard ratios: malignancy 4.53; coma 4.19; thrombosis of the deep venous system 3.03; mental status disturbance 2.18; male gender 1.60; intracranial haemorrhage 1.42) had overall efficiencies of 85.1, 84.4 and 90.0%, in the derivation sample and validation samples 1 and 2, respectively. Using the risk score (range from 0 to 9) with a cut-off of \u22653 points, overall efficiency was 85.4, 84.4 and 90.1% in the derivation sample and validation samples 1 and 2, respectively. Sensitivity and specificity in the combined samples were 96.1 and 13.6%, respectively. <i>Conclusions:<\/i> The CVT risk score has a good estimated overall rate of correct classifications in both validation samples, but its specificity is low. It can be used to avoid unnecessary or dangerous interventions in low-risk patients, and may help to identify high-risk CVT patients.<\/jats:p>","DOI":"10.1159\/000215942","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T11:20:34Z","timestamp":1242645634000},"page":"39-44","source":"Crossref","is-referenced-by-count":104,"title":["Risk Score to Predict the Outcome of Patients with Cerebral Vein and Dural Sinus Thrombosis"],"prefix":"10.1159","volume":"28","author":[{"given":"Jos\u00e9 M.","family":"Ferro","sequence":"first","affiliation":[]},{"given":"Helena","family":"Bacelar-Nicolau","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Leonor","family":"Bacelar-Nicolau","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Canh\u00e3o","sequence":"additional","affiliation":[]},{"given":"Isabelle","family":"Crassard","sequence":"additional","affiliation":[]},{"given":"Marie-Germaine","family":"Bousser","sequence":"additional","affiliation":[]},{"given":"Aur\u00e9lio Pimenta","family":"Dutra","sequence":"additional","affiliation":[]},{"given":"Ayrton","family":"Massaro","sequence":"additional","affiliation":[]},{"given":"Marie-Anne","family":"Mackowiack-Cordiolani","sequence":"additional","affiliation":[]},{"given":"Didier","family":"Leys","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Fontes","sequence":"additional","affiliation":[]},{"given":"Jan","family":"Stam","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Barinagarrementeria","sequence":"additional","affiliation":[]}],"member":"127","published-online":{"date-parts":[[2009,5,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000117571.76197.26"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2005-12-4795"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2FS1052-3057%2810%2980032-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000173152.84438.1c"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159%2F000057855"}],"container-title":["Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/215942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:38:51Z","timestamp":1745447931000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000215942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000215942","archive":["Portico"],"relation":{},"ISSN":["1015-9770","1421-9786"],"issn-type":[{"value":"1015-9770","type":"print"},{"value":"1421-9786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}